Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 90 | 21% |
| 2020 | 4 | 117 | 25% |
| 2021 | 2 | 77 | 29% |
| 2022 | 2 | 123 | 33% |
| 2023 | 1 | 92 | 37% |
| 2024 | 2 | 101 | 39% |
| 2025 from claims | – | 127 102–149 | 40% |
| 2026 forecast | – | 145 114–183 | 35% |
| 2027 forecast | – | 156 116–206 | 34% |
| 2028 forecast | – | 168 119–232 | 34% |
| 2029 forecast | – | 180 123–259 | 33% |
| 2030 forecast | – | 194 127–288 | 33% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Hampshire; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 54% hospital outpatient, 46% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 32 | 1,028−1.4%/yr | −1.4%/yr | 0.7 | 32% | 980 in 2030−0.7%/yr |
| New York | 12 | 563−6.5%/yr | −6.5%/yr | 0.3 | 16% | 550 in 2030−0.3%/yr |
| New Jersey | 12 | 392−5%/yr | −5%/yr | 0.4 | 70% | 450 in 2030+2.2%/yr |
| Massachusetts | 5 | 264−7.2%/yr | −7.2%/yr | 0.3 | 15% | 380 in 2030+6.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 34 | 2,030+2.3%/yr | +2.3%/yr | 8.71.2× | 67% | 3,060 in 2030+7.1%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with Pennsylvania
Boston Scientific leads with 59% of company spending on these surgeons in 2025, +23 pts on 2024.
In 2025, 7 companies reported engagement with New Hampshire’s surgeons worth $35K in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.